OR WAIT null SECS
The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.
Lonza announced on June 23, 2021 that the company has a manufacturing agreement with CellPoint, a clinical-stage biopharmaceutical company, to develop T-cell therapies for treating various cancers. The collaboration will use Lonza’s proprietary Cocoon Platform, an automated, closed patient-scale cell therapy manufacturing platform.
“We look forward to collaborating with CellPoint to accelerate and enable bringing novel cancer immunotherapies to the clinic and patients. The use of the Cocoon Platform, coupled with the array of CellPoints’ therapies and technologies, and Lonza’s manufacturing capabilities, will help to accelerate the path to the clinic and provide a smoother path to commercial approval. This collaboration also aims to illustrate the promise and feasibility of manufacturing autologous immunotherapies at the point-of-care by leveraging Cocoon’s unique platform capabilities,” said Eytan Abraham, head of Personalized Medicine at Lonza, in a press release.
“CellPoint has selected Lonza’s Cocoon Platform as the next-generation state-of-the-art closed and automated manufacturing device to develop its point-of-care strategy to make CAR-T affordable and more readily accessible. Over the past year, we have been working with Lonza to develop a manufacturing process that will allow a six to seven day vein-to-vein time to treat cancer patients,” said Tol Trimborn, Chief Executive Officer, CellPoint, in the release.